{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:15:42Z","timestamp":1774880142785,"version":"3.50.1"},"reference-count":82,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/14712598.2025.2479631","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T18:54:23Z","timestamp":1742410463000},"page":"331-343","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["An evaluation of odronextamab for the treatment of multiple subtypes of relapsed\/refractory B-cell non-Hodgkin lymphoma"],"prefix":"10.1080","volume":"25","author":[{"given":"Elena","family":"Bayly-McCredie","sequence":"first","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]},{"name":"The University of Melbourne","place":["Melbourne, Australia"]},{"name":"Monash University","place":["Melbourne, Australia"]},{"name":"Sir Peter MacCallum Cancer Centre","place":["Melbourne, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas Kleanthes","family":"Yannakou","sequence":"additional","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]},{"name":"The University of Melbourne","place":["Melbourne, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Fiorenza","sequence":"additional","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]},{"name":"Department of Clinical Haematology","place":["Alfred Health, Melbourne, Australia"]},{"name":"University of Sydney","place":["Camperdown, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-020-09729-7"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34163"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179736"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.003"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006245"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2321648"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-2-4"},{"key":"e_1_3_6_14_1","unstructured":"Food US Administration D. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. 2022 [cited 2024 Nov 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma"},{"key":"e_1_3_6_15_1","unstructured":"Food US Administration D. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. 2023 [cited 2024 Nov 3]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell"},{"key":"e_1_3_6_16_1","unstructured":"Food US Administration D. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. 2023 [cited 2024 Nov 3]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell#:~:text=On%20June%2015%2C%202023%2C%20the Columvi%2C%20Genentech%2C%20Inc"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4501.4501"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975800.84791.f4"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975832.38492.3b"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000976060.06798.be"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000976092.30614.25"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7094"},{"key":"e_1_3_6_25_1","unstructured":"Regeneron Provides Update on Biologics License Application for Odronextamab. Press release. TARRYTOWN N.Y: Regeneron Pharmaceuticals Inc; 2024 Mar 25 [cited 2024 Nov 3]. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-provides-update-biologics-license-application"},{"key":"e_1_3_6_26_1","unstructured":"Ordspono\u2122 (odronextamab). Approved in the European Union for the treatment of Relapsed\/Refractory follicular lymphoma and diffuse large B-cell lymphoma [press release]. TARRYTOWN N.Y: Regeneron Pharmaceuticals Inc; 2024 Aug 26 [cited 2024 Nov 3]. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/ordsponotm-odronextamab-approved-european-union-treatment"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep17943"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900496"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/9.7.617"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01564"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1967714"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00989-w"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23788"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00871-z"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.818.818"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0001-1"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_6_39_1","doi-asserted-by":"crossref","unstructured":"Bannerji R Brown JR Advani RH et al. Phase 1 study of REGN1979 an anti-CD20 x anti-CD3 bispecific monoclonal antibody in patients with CD20+ B-cell malignancies previously treated with CD20-directed antibody therapy. Blood conference: 58th annual meeting of the American Society of Hematology ASH. 2016;128(22):621.","DOI":"10.1182\/blood.V128.22.621.621"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136659"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181602"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158409"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158412"},{"key":"e_1_3_6_44_1","unstructured":"An open-label study to assess the anti-tumor activity and safety of REGN1979 an anti CD20 x anti-CD3 Bispecific antibody in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma [Internet]. 2019 [cited 2024 Nov 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03888105"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971356.50570.ac"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200190"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200150"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00921-6"},{"issue":"1","key":"e_1_3_6_49_1","article-title":"Safety and preliminary antitumor activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979, an anti-CD20 X anti-CD3 bispecific antibody, in patients with B-lymphoid malignancies","volume":"130","author":"Topp MS","year":"2017","unstructured":"Topp MS, Borchmann P, Wagner-Johnston ND, et al. Safety and preliminary antitumor activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979, an anti-CD20 X anti-CD3 bispecific antibody, in patients with B-lymphoid malignancies. Blood Conf 59th Annu Meet Of The Am Soc Of Hematol, ASH. 2017;130(Supplement 1):3100.","journal-title":"Blood Conf 59th Annu Meet Of The Am Soc Of Hematol, ASH"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000976032.70825.65"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178658"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179964"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199155"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199980"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_6_56_1","unstructured":"Regeneron resumes enrollment of FL and DLBCL patients in Odronextamab trials. Press release. TARRYTOWN N.Y: Regeneron Pharmaceuticals Inc; 2021 May 17 [cited 2024 Nov 3]. Available from: https:\/\/invesor.regeneron.com\/static-files\/f926fedf-8c6c-4f6f-a110-f295978c0c7f"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433516"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200150"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022348"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008338"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1082"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02726-5"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3150"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012916"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200623"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.005"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19668"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0049"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14076"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005954"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0038"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001797"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285255"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024526"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2479631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:21:10Z","timestamp":1744179670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2479631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/14712598.2025.2479631"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2479631","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}